Trial
NCT01712074
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Pfizer
Collaborators
—
Condition
Alzheimer's Disease
Intervention
PF-05212377 (SAM-760)
Why stopped
The study was terminated October 23, 2015 as pre-specified, interim analysis futility criteria were met. The termination was not due to safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-03-20